TNFRSF17 and lymphoma: Hence, dual targeting of CD19 and BCMA offers the prospect of a broadly applicable therapeutic product that can be used in a spectrum of B-cell hematological malignancies ranging from B-cell leukemia and lymphoma to multiple myeloma.